Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 3;7(2):e10327.
doi: 10.1002/lrh2.10327. eCollection 2023 Apr.

Evolving a national clinical trials learning health system

Affiliations

Evolving a national clinical trials learning health system

Kristian D Stensland et al. Learn Health Syst. .

Abstract

Clinical trials generate key evidence to inform decision making, and also benefit participants directly. However, clinical trials frequently fail, often struggle to enroll participants, and are expensive. Part of the problem with trial conduct may be the disconnected nature of clinical trials, preventing rapid data sharing, generation of insights and targeted improvement interventions, and identification of knowledge gaps. In other areas of healthcare, a learning health system (LHS) has been proposed as a model to facilitate continuous learning and improvement. We propose that an LHS approach could greatly benefit clinical trials, allowing for continuous improvements to trial conduct and efficiency. A robust trial data sharing system, continuous analysis of trial enrollment and other success metrics, and development of targeted trial improvement interventions are potentially key components of a Trials LHS reflecting the learning cycle and allowing for continuous trial improvement. Through the development and use of a Trials LHS, clinical trials could be treated as a system, producing benefits to patients, advancing care, and decreasing costs for stakeholders.

Keywords: clinical trials; continuous improvement; learning cycle; learning health system.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

Similar articles

Cited by

References

    1. Denburg A, Rodriguez‐Galindo C, Joffe S. Clinical trials infrastructure as a quality improvement intervention in low‐ and middle‐income countries. Am J Bioeth. 2016;16:3‐11. - PubMed
    1. Grand View Research . Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication, By Region, And Segment Forecasts 2021–2028; 2021. https://www.grandviewresearch.com/industry-analysis/global-clinical-tria.... Accessed 30 July, 2021.
    1. Khunger M, Rakshit S, Hernandez AV, et al. Premature clinical trial discontinuation in the era of immune checkpoint inhibitors. Oncologist. 2018;23:1494‐1499. - PMC - PubMed
    1. Stensland KD, McBride RB, Latif A, et al. Adult cancer clinical trials that fail to complete: an epidemic? J Natl Cancer Inst. 2014;106. - PubMed
    1. Stensland K, Kaffenberger S, Canes D, Galsky M, Skolarus T, Moinzadeh A. Assessing genitourinary cancer clinical trial accrual sufficiency using archived trial data. JCO Clin Cancer Inform. 2020;4:614‐622. - PubMed

LinkOut - more resources